Perte de poids

Fatigue with Mounjaro: Causes and How to Regain Energy

by

Fatigue with Mounjaro affects approximately 10 to 15% of patients. Discover its causes and how to regain your energy during treatment. Fatigue is an often underestimated side effect of tirzepatide. While rarely mentioned as a reason for discontinuation in clinical studies, it significantly impacts the quality of life of about 10 to 15% … Read more

Nausea with Mounjaro: Causes, Duration, and Practical Solutions

by

Nausea is the most common side effect with Mounjaro. Here’s a comprehensive guide to understanding, preventing, and effectively treating it. Between 24% and 33% of patients on tirzepatide experience nausea, primarily at the beginning of treatment and during dose escalations. Although generally transient, this nausea can significantly affect quality of life and lead some patients to discontinue treatment. … Read more

Mounjaro and Heart Failure: The SUMMIT Study

by

The SUMMIT study demonstrates that tirzepatide significantly improves symptoms and prognosis of heart failure in obese patients. Heart failure with preserved ejection fraction (HFpEF) is one of the most frequent and challenging forms of heart failure to treat, particularly affecting obese patients. The SUMMIT study, published in the New England … Read more

Tirzepatide in Obese Adolescents: The SURMOUNT-Jr Study

by

The SURMOUNT-Jr study paves the way for the treatment of severe obesity in adolescents with tirzepatide, showing superior results to any existing treatment. Pediatric obesity is a global public health crisis. In France, approximately 18% of children and adolescents are overweight or obese, with major physical and psychological consequences. The SURMOUNT-Jr study, … Read more

Weight Regain After Tirzepatide Discontinuation: What Do the Data Say?

by

Discontinuing tirzepatide leads to weight regain in the majority of patients. Here are the scientific data and strategies to limit this phenomenon. One of the most important questions for patients on Mounjaro is: what happens when treatment is stopped? Data from the SURMOUNT-4 study and observational studies provide … Read more

Plateau effect under Mounjaro: understanding and overcoming stagnation

by

Weight stagnation under Mounjaro is a frequent and predictable phenomenon. Understanding its mechanisms allows it to be overcome. After several months of regular weight loss with tirzepatide, many patients reach a plateau: weight stabilizes despite continued treatment and dietary efforts. This phenomenon, a source of frustration and … Read more

Tirzepatide and Fatty Liver Disease (NASH): Promising Results

by

Tirzepatide could become the first effective drug treatment for non-alcoholic steatohepatitis (NASH), a disease affecting millions of French people. Non-alcoholic fatty liver disease (NAFLD), and its progressive form, steatohepatitis (NASH), represent one of the greatest silent epidemics of the 21st century. In France, it is estimated that 18 to 25% of … Read more

Mounjaro and Sleep Apnea: Results of the SURMOUNT-OSA Study

by

The SURMOUNT-OSA study demonstrates that tirzepatide significantly reduces the severity of obstructive sleep apnea, offering an alternative to mechanical treatments. Obstructive sleep apnea (OSA) affects approximately 30 to 40% of obese individuals. This condition, characterized by repeated interruptions of breathing during sleep, increases cardiovascular risk and significantly deteriorates … Read more

SURPASS-CVOT: Does Mounjaro Reduce Cardiovascular Risk?

by

The SURPASS-CVOT study is the largest cardiovascular trial ever conducted with tirzepatide. Its results could transform treatment recommendations. The question of cardiovascular safety for anti-obesity treatments is fundamental. The SURPASS-CVOT (Cardiovascular Outcomes Trial) study was designed to evaluate whether tirzepatide (Mounjaro) reduces the risk of major cardiovascular events in patients … Read more